Held from May 17th to 19th, the conference served as a global platform for researchers and healthcare professionals to delve into the latest advancements in understanding, preventing, and treating blood clots in cancer patients.
Thrombosis poses a significant health risk for cancer patients, and ICTHIC 2024 provided a critical forum for sharing knowledge and developing strategies to improve patient outcomes. Werfen's sponsorship underscores their dedication to progress in the field of hematology, particularly in the fight against cancer. Their diagnostic tools play a vital role in managing blood clotting disorders, and their participation in the conference signifies their commitment to enhancing patient care.
This involvement played a crucial role in ensuring the dissemination of the latest research on thrombosis and hemostasis in cancer to a wider audience. Ultimately, Werfen's contribution to ICTHIC 2024 paves the way for better patient care and improved outcomes for cancer patients globally.
As a company focused on Powering Patient Care for Thrombosis and Hemostasis issues we are keen on highlighting the impact on outcomes of proper diagnosis and assessment of thrombotic risks.
For more information on educational material related to the specific topic of Cancer Associated Thrombosis on our EEMEA Learning Center.
- Congress Report ICTHIC 2022
- Congress Report ICTHIC 2024
- Hemostasis Biomarkers and Cancer - Findings from the HYPERCAN Study
- Cancer Associated Thrombosis
- Risk Assessment for VTE in Cancer
- D-Dimer in Cancer and VTE
Additional Resources:
We look forward to seeing everyone in the next edition of this important conference.
Elias El Bouchi, Marketing Manager Hemostasis



